<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00316082</url>
  </required_header>
  <id_info>
    <org_study_id>CV181-038</org_study_id>
    <nct_id>NCT00316082</nct_id>
  </id_info>
  <brief_title>Study of BMS-477118 as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of this trial is to understand if saxagliptin is more effective than placebo as a
      treatment for type 2 diabetic subjects who are not controlled with diet and exercise
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All subjects will participate in a lead-in period, and qualifying subjects will continue into
      a short-term randomized treatment period. Subjects who complete the short-term period will be
      eligible to enter the long term extension period. Also, subjects in the short-term period who
      have an elevated blood sugar that requires additional medication for blood sugar control will
      be eligible to enter the long-term treatment extension period where they will receive
      metformin (rescue medication) added onto their blinded study medication
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Hemoglobin A1 (A1C) at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Mean change from baseline in A1C at Week 24, adjusted for baseline value.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in A1C at Week 24 - Saxagliptin 5 mg QPM</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Mean change from baseline in A1C at Week 24, adjusted for baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Mean change from baseline in FPG at Week 24, adjusted for baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving A1C &lt; 7% at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Percentage of participants achieving A1C &lt; 7%, the American Diabetes Association's defined goal for glycemia, at each dose of saxagliptin versus placebo at Week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline in Postprandial Glucose (PPG) Area Under the Curve (AUC) Response to an Oral Glucose Tolerance Test (OGTT) at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Mean change from baseline for 0 to 180 minutes PPG AUC at Week 24, adjusted for baseline value.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">365</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Saxagliptin 2.5 mg QAM (A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PLUS open-label metformin (as needed as rescue medication)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saxagliptin 2.5 mg titrated to 5 mg QAM (B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PLUS open-label metformin (as needed as rescue medication)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saxagliptin 5 mg QAM (C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PLUS open-label metformin (as needed as rescue medication)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saxagliptin 5 mg QPM (D)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PLUS open-label metformin (as needed as rescue medication)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (E)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PLUS open-label metformin (as needed as rescue medication)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saxagliptin</intervention_name>
    <description>Coated tablets, Oral, 2.5 mg, QAM, Daily (6 months ST, 12 months LT)</description>
    <arm_group_label>Saxagliptin 2.5 mg QAM (A)</arm_group_label>
    <other_name>BMS-477118</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saxagliptin</intervention_name>
    <description>Coated tablets, Oral, 2.5 mg titrated to 5mg, QAM, Daily (6 months ST, 12 months LT)</description>
    <arm_group_label>Saxagliptin 2.5 mg titrated to 5 mg QAM (B)</arm_group_label>
    <other_name>BMS-477118</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saxagliptin</intervention_name>
    <description>Coated tablets, Oral, 5mg, QAM, Daily, (6 months ST, 12 months LT)</description>
    <arm_group_label>Saxagliptin 5 mg QAM (C)</arm_group_label>
    <other_name>BMS-477118</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saxagliptin</intervention_name>
    <description>Coated tablets, Oral, 5mg QPM, Daily (6 months ST, 12 months LT)</description>
    <arm_group_label>Saxagliptin 5 mg QPM (D)</arm_group_label>
    <other_name>BMS-477118</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Coated tablets, Oral, 0mg, Daily (6 months ST, 12 months LT)</description>
    <arm_group_label>Placebo (E)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <description>Tablets, Oral, 500-2000 mg, as needed (12 months LT)</description>
    <arm_group_label>Saxagliptin 2.5 mg QAM (A)</arm_group_label>
    <arm_group_label>Saxagliptin 2.5 mg titrated to 5 mg QAM (B)</arm_group_label>
    <arm_group_label>Saxagliptin 5 mg QAM (C)</arm_group_label>
    <arm_group_label>Saxagliptin 5 mg QPM (D)</arm_group_label>
    <arm_group_label>Placebo (E)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes

          -  Inadequate blood sugar control

        Exclusion Criteria:

          -  Previous treatment for diabetes

          -  Current treatment with other medications to lower blood sugar

          -  Major heart, liver or kidney problems

          -  Women who are pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>77 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tomac, Inc.</name>
      <address>
        <city>Columbiana</city>
        <state>Alabama</state>
        <zip>35051</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winston Technology, Inc.</name>
      <address>
        <city>Haleyville</city>
        <state>Alabama</state>
        <zip>35565</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Reseacrh Advantage/ Brown Family Medicine</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Strategos Medical Group</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Clinical Research</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rx For Life, Inc</name>
      <address>
        <city>Cudahy</city>
        <state>California</state>
        <zip>90201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Group Of Encino</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southland Clinical Research Center, Inc.</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Research</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Medical Center Of California</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>In Private Prictice Clinic</name>
      <address>
        <city>Pico Rivera</city>
        <state>California</state>
        <zip>90660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Jose Clinical Research, Inc.</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Florida Clinical Trials, Inc.</name>
      <address>
        <city>Altamonte Springs</city>
        <state>Florida</state>
        <zip>32714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accelovance</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32935</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Family Healthcare, Pa</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Healthcare</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinnacle Medical Research</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City University Of Medicine And Biosciences</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Care Physicians, Pc</name>
      <address>
        <city>Wentzville</city>
        <state>Missouri</state>
        <zip>63385</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physicians Research Center</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hudson Valley Clinical Research Center</name>
      <address>
        <city>Kingston</city>
        <state>New York</state>
        <zip>12401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neem Research Group Of Charlotte</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Center- East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crescent Medical Research</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Health Care, Inc.</name>
      <address>
        <city>Barberton</city>
        <state>Ohio</state>
        <zip>44203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Limited</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wells Institute For Health Awareness</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <zip>45429</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Source, Inc</name>
      <address>
        <city>Perrysburg</city>
        <state>Ohio</state>
        <zip>43551</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accelovance</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integris Family Care South</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73170</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Office Of Patricia Buchanan</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cumberland Valley Endocrinology Center, Llc</name>
      <address>
        <city>Carlisle</city>
        <state>Pennsylvania</state>
        <zip>17015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fleetwood Clinical Research</name>
      <address>
        <city>Fleetwood</city>
        <state>Pennsylvania</state>
        <zip>19522</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Banksville Medical, Pc</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biomedical Research Associates, Llc</name>
      <address>
        <city>Shippensburg</city>
        <state>Pennsylvania</state>
        <zip>17257</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Middle Tyger Family Medicine</name>
      <address>
        <city>Duncan</city>
        <state>South Carolina</state>
        <zip>29334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Research Assoc</name>
      <address>
        <city>Taylors</city>
        <state>South Carolina</state>
        <zip>29687</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Versoza &amp; Ungab Internal Medicine Associates</name>
      <address>
        <city>Bartlett</city>
        <state>Tennessee</state>
        <zip>38134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Collierville Medical Specialist</name>
      <address>
        <city>Collierville</city>
        <state>Tennessee</state>
        <zip>38017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holston Medical Group</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med-South Research</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwind Medical Specialist</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precision Family Medicine</name>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <zip>75010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alpha Therapy Research Center</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78411</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Village Family Practice</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Center For Drug Development, P.A.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abbott Clinical Research Group, Inc</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taylor/Wade Medical</name>
      <address>
        <city>Bountiful</city>
        <state>Utah</state>
        <zip>84010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimum Clinical Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tidewater Integrated Medical Research</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23451</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spokane Internal Medicine</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Manipal</city>
        <state>Karnataka</state>
        <zip>576104</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kochi</city>
        <state>Kerala</state>
        <zip>682026</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Attavar</city>
        <state>Mangalore</state>
        <zip>575001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sarita Vihar</city>
        <state>New Delhi</state>
        <zip>110076</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bangalore</city>
        <zip>560034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mumbai</city>
        <zip>400007</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mumbai</city>
        <zip>400021</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nagpur</city>
        <zip>440012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Moscov</city>
        <zip>118089</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Moscow</city>
        <zip>115487</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>198013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Saratov</city>
        <zip>410018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Saratov</city>
        <zip>410054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Smolensk</city>
        <zip>214018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>St.Petersburg</city>
        <zip>194156</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Volgograd</city>
        <zip>400138</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Changhua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kaohsiung County</city>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Taichung City</city>
        <zip>407</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Taichung</city>
        <zip>402</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Taipei City</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tao-Yuan County</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
    <country>Russian Federation</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2006</study_first_submitted>
  <study_first_submitted_qc>April 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2006</study_first_posted>
  <results_first_submitted>August 17, 2009</results_first_submitted>
  <results_first_submitted_qc>August 17, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 25, 2009</results_first_posted>
  <last_update_submitted>April 8, 2015</last_update_submitted>
  <last_update_submitted_qc>April 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Saxagliptin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Saxagliptin 2.5 mg Once in the Morning (QAM)</title>
          <description>The Saxagliptin 2.5 mg QAM group includes data from subjects randomized to receive administration of blinded Saxagliptin 2.5 mg oral tablets QAM daily.</description>
        </group>
        <group group_id="P2">
          <title>Saxagliptin 5 mg QAM</title>
          <description>The Saxagliptin 5 mg QAM group includes data from subjects randomized to receive administration of blinded Saxagliptin 5 mg oral tablets QAM daily.</description>
        </group>
        <group group_id="P3">
          <title>Saxagliptin 2.5/5 mg QAM</title>
          <description>The Saxagliptin 2.5/5 mg QAM group includes data from subjects randomized to receive administration of blinded Saxagliptin 2.5 mg oral tablets QAM daily, with possible titration to 5 mg oral tablets QAM.</description>
        </group>
        <group group_id="P4">
          <title>Saxagliptin 5 mg Once in the Evening (QPM)</title>
          <description>The Saxagliptin 5 mg QPM group includes data from subjects randomized to receive administration of blinded Saxagliptin 5 mg oral tablets QPM daily.</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>The Placebo group includes data from subjects randomized to receive administration of placebo oral tablets daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="74"/>
                <participants group_id="P3" count="71"/>
                <participants group_id="P4" count="72"/>
                <participants group_id="P5" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Study Without Being Rescued</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="27"/>
                <participants group_id="P5" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="44"/>
                <participants group_id="P4" count="46"/>
                <participants group_id="P5" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="27"/>
                <participants group_id="P4" count="26"/>
                <participants group_id="P5" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal of Consent by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor/noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject no longer meets study criteria</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative reason by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Saxagliptin 2.5 mg Once in the Morning (QAM)</title>
          <description>The Saxagliptin 2.5 mg QAM group includes data from subjects randomized to receive administration of blinded Saxagliptin 2.5 mg oral tablets QAM daily.</description>
        </group>
        <group group_id="B2">
          <title>Saxagliptin 5 mg QAM</title>
          <description>The Saxagliptin 5 mg QAM group includes data from subjects randomized to receive administration of blinded Saxagliptin 5 mg oral tablets QAM daily.</description>
        </group>
        <group group_id="B3">
          <title>Saxagliptin 2.5/5 mg QAM</title>
          <description>The Saxagliptin 2.5/5 mg QAM group includes data from subjects randomized to receive administration of blinded Saxagliptin 2.5 mg oral tablets QAM daily, with possible titration to 5 mg oral tablets QAM.</description>
        </group>
        <group group_id="B4">
          <title>Saxagliptin 5 mg Once in the Evening (QPM)</title>
          <description>The Saxagliptin 5 mg QPM group includes data from subjects randomized to receive administration of blinded Saxagliptin 5 mg oral tablets QPM daily.</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>The Placebo group includes data from subjects randomized to receive administration of placebo oral tablets daily.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="74"/>
            <count group_id="B2" value="74"/>
            <count group_id="B3" value="71"/>
            <count group_id="B4" value="72"/>
            <count group_id="B5" value="74"/>
            <count group_id="B6" value="365"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.24" spread="10.44"/>
                    <measurement group_id="B2" value="54.66" spread="9.71"/>
                    <measurement group_id="B3" value="54.28" spread="10.93"/>
                    <measurement group_id="B4" value="55.11" spread="10.35"/>
                    <measurement group_id="B5" value="55.57" spread="10.32"/>
                    <measurement group_id="B6" value="54.98" spread="10.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="39"/>
                    <measurement group_id="B6" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="35"/>
                    <measurement group_id="B6" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hemoglobin A1 (A1C) at Week 24</title>
        <description>Mean change from baseline in A1C at Week 24, adjusted for baseline value.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Randomized participants who took at least 1 dose of double-blind treatment. To be included in analysis of change from baseline to Week 24 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement. If participant received rescue medication, measurement must have been taken before rescue.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg QAM</title>
            <description>The Saxagliptin 2.5 mg QAM group includes data from subjects randomized to receive administration of blinded Saxagliptin 2.5 mg oral tablets QAM daily.</description>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg QAM</title>
            <description>The Saxagliptin 5 mg QAM group includes data from subjects randomized to receive administration of blinded Saxagliptin 5 mg oral tablets QAM daily.</description>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 2.5/5 mg QAM</title>
            <description>The Saxagliptin 2.5/5 mg QAM group includes data from subjects randomized to receive administration of blinded Saxagliptin 2.5 mg oral tablets QAM daily, with possible titration to 5 mg oral tablets QAM.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>The Placebo group includes data from subjects randomized to receive administration of placebo oral tablets daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemoglobin A1 (A1C) at Week 24</title>
          <description>Mean change from baseline in A1C at Week 24, adjusted for baseline value.</description>
          <population>Randomized participants who took at least 1 dose of double-blind treatment. To be included in analysis of change from baseline to Week 24 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement. If participant received rescue medication, measurement must have been taken before rescue.</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Mean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.04" spread="0.105"/>
                    <measurement group_id="O2" value="7.93" spread="0.106"/>
                    <measurement group_id="O3" value="8.02" spread="0.131"/>
                    <measurement group_id="O4" value="7.79" spread="0.112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 Mean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.30" spread="0.106"/>
                    <measurement group_id="O2" value="7.27" spread="0.129"/>
                    <measurement group_id="O3" value="7.37" spread="0.137"/>
                    <measurement group_id="O4" value="7.57" spread="0.141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adjusted Mean Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.71" spread="0.103"/>
                    <measurement group_id="O2" value="-0.66" spread="0.102"/>
                    <measurement group_id="O3" value="-0.63" spread="0.102"/>
                    <measurement group_id="O4" value="-0.26" spread="0.103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in A1C at Week 24 - Saxagliptin 5 mg QPM</title>
        <description>Mean change from baseline in A1C at Week 24, adjusted for baseline value.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Randomized participants who took at least 1 dose of double-blind treatment. To be included in analysis of change from baseline to Week 24 LOCF, participants must have had a baseline and at least 1 post-baseline measurement. If a participant received rescue medication, then that measurement must have been taken before rescue.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 5 mg QPM</title>
            <description>The Saxagliptin 5 mg QPM group includes data from subjects randomized to receive administration of blinded Saxagliptin 5 mg oral tablets QPM daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>The Placebo group includes data from subjects randomized to receive administration of placebo oral tablets daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in A1C at Week 24 - Saxagliptin 5 mg QPM</title>
          <description>Mean change from baseline in A1C at Week 24, adjusted for baseline value.</description>
          <population>Randomized participants who took at least 1 dose of double-blind treatment. To be included in analysis of change from baseline to Week 24 LOCF, participants must have had a baseline and at least 1 post-baseline measurement. If a participant received rescue medication, then that measurement must have been taken before rescue.</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Mean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.88" spread="0.111"/>
                    <measurement group_id="O2" value="7.79" spread="0.112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 Mean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.29" spread="0.124"/>
                    <measurement group_id="O2" value="7.57" spread="0.141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adjusted Mean Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.61" spread="0.101"/>
                    <measurement group_id="O2" value="-0.26" spread="0.103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24</title>
        <description>Mean change from baseline in FPG at Week 24, adjusted for baseline value.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Randomized participants who took at least 1 dose of double-blind treatment. To be included in analysis of change from baseline to Week 24 LOCF, participants must have had a baseline and at least 1 post-baseline measurement. If a participant received rescue medication, then that measurement must have been taken before rescue.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg Once in the Morning (QAM)</title>
            <description>The Saxagliptin 2.5 mg QAM group includes data from subjects randomized to receive administration of blinded Saxagliptin 2.5 mg oral tablets QAM daily.</description>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg QAM</title>
            <description>The Saxagliptin 5 mg QAM group includes data from subjects randomized to receive administration of blinded Saxagliptin 5 mg oral tablets QAM daily.</description>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 2.5/5 mg QAM</title>
            <description>The Saxagliptin 2.5/5 mg QAM group includes data from subjects randomized to receive administration of blinded Saxagliptin 2.5 mg oral tablets QAM daily, with possible titration to 5 mg oral tablets QAM.</description>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 5 mg Once in the Evening (QPM)</title>
            <description>The Saxagliptin 5 mg QPM group includes data from subjects randomized to receive administration of blinded Saxagliptin 5 mg oral tablets QPM daily.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>The Placebo group includes data from subjects randomized to receive administration of placebo oral tablets daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24</title>
          <description>Mean change from baseline in FPG at Week 24, adjusted for baseline value.</description>
          <population>Randomized participants who took at least 1 dose of double-blind treatment. To be included in analysis of change from baseline to Week 24 LOCF, participants must have had a baseline and at least 1 post-baseline measurement. If a participant received rescue medication, then that measurement must have been taken before rescue.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="71"/>
                <count group_id="O5" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Mean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156.6" spread="3.96"/>
                    <measurement group_id="O2" value="162.2" spread="4.24"/>
                    <measurement group_id="O3" value="170.6" spread="6.15"/>
                    <measurement group_id="O4" value="159.6" spread="5.32"/>
                    <measurement group_id="O5" value="158.6" spread="5.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 Mean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146.8" spread="3.79"/>
                    <measurement group_id="O2" value="151.3" spread="5.88"/>
                    <measurement group_id="O3" value="155.2" spread="5.88"/>
                    <measurement group_id="O4" value="152.4" spread="5.88"/>
                    <measurement group_id="O5" value="162.9" spread="6.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adjusted Mean Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.4" spread="4.50"/>
                    <measurement group_id="O2" value="-10.7" spread="4.46"/>
                    <measurement group_id="O3" value="-12.5" spread="4.48"/>
                    <measurement group_id="O4" value="-7.9" spread="4.46"/>
                    <measurement group_id="O5" value="3.3" spread="4.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving A1C &lt; 7% at Week 24</title>
        <description>Percentage of participants achieving A1C &lt; 7%, the American Diabetes Association’s defined goal for glycemia, at each dose of saxagliptin versus placebo at Week 24.</description>
        <time_frame>Week 24</time_frame>
        <population>Randomized participants who took at least 1 dose of double-blind treatment. To be included in the Week 24 LOCF analysis, participants must have had at least 1 post-baseline measurement. If a participant received rescue medication, then that measurement must have been taken before rescue.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg Once in the Morning (QAM)</title>
            <description>The Saxagliptin 2.5 mg QAM group includes data from subjects randomized to receive administration of blinded Saxagliptin 2.5 mg oral tablets QAM daily.</description>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg QAM</title>
            <description>The Saxagliptin 5 mg QAM group includes data from subjects randomized to receive administration of blinded Saxagliptin 5 mg oral tablets QAM daily.</description>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 2.5/5 mg QAM</title>
            <description>The Saxagliptin 2.5/5 mg QAM group includes data from subjects randomized to receive administration of blinded Saxagliptin 2.5 mg oral tablets QAM daily, with possible titration to 5 mg oral tablets QAM.</description>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 5 mg Once in the Evening (QPM)</title>
            <description>The Saxagliptin 5 mg QPM group includes data from subjects randomized to receive administration of blinded Saxagliptin 5 mg oral tablets QPM daily.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>The Placebo group includes data from subjects randomized to receive administration of placebo oral tablets daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving A1C &lt; 7% at Week 24</title>
          <description>Percentage of participants achieving A1C &lt; 7%, the American Diabetes Association’s defined goal for glycemia, at each dose of saxagliptin versus placebo at Week 24.</description>
          <population>Randomized participants who took at least 1 dose of double-blind treatment. To be included in the Week 24 LOCF analysis, participants must have had at least 1 post-baseline measurement. If a participant received rescue medication, then that measurement must have been taken before rescue.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.8"/>
                    <measurement group_id="O2" value="44.9"/>
                    <measurement group_id="O3" value="43.5"/>
                    <measurement group_id="O4" value="38.6"/>
                    <measurement group_id="O5" value="35.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline in Postprandial Glucose (PPG) Area Under the Curve (AUC) Response to an Oral Glucose Tolerance Test (OGTT) at Week 24</title>
        <description>Mean change from baseline for 0 to 180 minutes PPG AUC at Week 24, adjusted for baseline value.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Randomized participants who took at least 1 dose of double-blind treatment. To be included in analysis of change from baseline to Week 24 LOCF, participants must have had a baseline and at least 1 post-baseline measurement. If a participant received rescue medication, then that measurement must have been taken before rescue.</population>
        <group_list>
          <group group_id="O1">
            <title>Saxagliptin 2.5 mg Once in the Morning (QAM)</title>
            <description>The Saxagliptin 2.5 mg QAM group includes data from subjects randomized to receive administration of blinded Saxagliptin 2.5 mg oral tablets QAM daily.</description>
          </group>
          <group group_id="O2">
            <title>Saxagliptin 5 mg QAM</title>
            <description>The Saxagliptin 5 mg QAM group includes data from subjects randomized to receive administration of blinded Saxagliptin 5 mg oral tablets QAM daily.</description>
          </group>
          <group group_id="O3">
            <title>Saxagliptin 2.5/5 mg QAM</title>
            <description>The Saxagliptin 2.5/5 mg QAM group includes data from subjects randomized to receive administration of blinded Saxagliptin 2.5 mg oral tablets QAM daily, with possible titration to 5 mg oral tablets QAM.</description>
          </group>
          <group group_id="O4">
            <title>Saxagliptin 5 mg Once in the Evening (QPM)</title>
            <description>The Saxagliptin 5 mg QPM group includes data from subjects randomized to receive administration of blinded Saxagliptin 5 mg oral tablets QPM daily.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>The Placebo group includes data from subjects randomized to receive administration of placebo oral tablets daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline in Postprandial Glucose (PPG) Area Under the Curve (AUC) Response to an Oral Glucose Tolerance Test (OGTT) at Week 24</title>
          <description>Mean change from baseline for 0 to 180 minutes PPG AUC at Week 24, adjusted for baseline value.</description>
          <population>Randomized participants who took at least 1 dose of double-blind treatment. To be included in analysis of change from baseline to Week 24 LOCF, participants must have had a baseline and at least 1 post-baseline measurement. If a participant received rescue medication, then that measurement must have been taken before rescue.</population>
          <units>mg*min/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="43"/>
                <count group_id="O5" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Mean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47432" spread="1496.6"/>
                    <measurement group_id="O2" value="50417" spread="1561.5"/>
                    <measurement group_id="O3" value="50032" spread="1684.7"/>
                    <measurement group_id="O4" value="47078" spread="1941.9"/>
                    <measurement group_id="O5" value="47640" spread="1759.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 Mean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39798" spread="1347.0"/>
                    <measurement group_id="O2" value="41562" spread="1489.3"/>
                    <measurement group_id="O3" value="41745" spread="1739.2"/>
                    <measurement group_id="O4" value="41530" spread="1962.7"/>
                    <measurement group_id="O5" value="44861" spread="1854.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adjusted Mean Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8014" spread="1246.9"/>
                    <measurement group_id="O2" value="-8218" spread="1249.1"/>
                    <measurement group_id="O3" value="-7781" spread="1261.0"/>
                    <measurement group_id="O4" value="-6048" spread="1318.2"/>
                    <measurement group_id="O5" value="-3088" spread="1259.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>The Placebo group includes data from subjects randomized to receive administration of placebo oral tablets daily.</description>
        </group>
        <group group_id="E2">
          <title>Saxagliptin 2.5/5 mg QAM</title>
          <description>The Saxagliptin 2.5/5 mg QAM group includes data from subjects randomized to receive administration of blinded Saxagliptin 2.5 mg oral tablets QAM daily, with possible titration to 5 mg oral tablets QAM.</description>
        </group>
        <group group_id="E3">
          <title>Saxagliptin 2.5 mg QAM</title>
          <description>The Saxagliptin 2.5 mg QAM group includes data from subjects randomized to receive administration of blinded Saxagliptin 2.5 mg oral tablets QAM daily.</description>
        </group>
        <group group_id="E4">
          <title>Saxagliptin 5 mg QAM</title>
          <description>The Saxagliptin 5 mg QAM group includes data from subjects randomized to receive administration of blinded Saxagliptin 5 mg oral tablets QAM daily.</description>
        </group>
        <group group_id="E5">
          <title>Saxagliptin 5 mg QPM</title>
          <description>The Saxagliptin 5 mg QPM group includes data from subjects randomized to receive administration of blinded Saxagliptin 5 mg oral tablets QPM daily.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>COR PULMONALE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>RETINAL DETACHMENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>RECTAL POLYP</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>FOOD POISONING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>GASTRITIS EROSIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>INFECTED BITES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>PNEUMOCOCCAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>OVERDOSE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>LIGAMENT RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>FEMORAL NECK FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>SPINAL COMPRESSION FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>UTERINE CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>PANCREATIC CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>HEPATIC CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>CALCULUS URETERIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>INTERTRIGO</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>ARTERIAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="29" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>RHINITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>JOINT INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boaz Hirschberg</name_or_title>
      <organization>AstraZeneca Pharmaceuticals</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

